MA07.06 Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer

Tan, Aaron C.; Lai, Gillianne; Saw, Sharon; Chua, Kevin Lee Min; Takano, Angela; Ong, Boon-Hean; Koh, Tina; Jain, Amit; Tan, Wan Ling; Ng, Quan Sing; Kanesvaran, Ravindran; Rajasekaran, Tanujaa; Kalshnikova, E.; Shchegrova, Svetlana; Ta, Hong; Lin, J.; Renner, Derrick; Sethi, Himanshu; Zimmermann, Bernhard; Aleshin, Alexey; Lim, Wan-Teck; Tan, Eng Huat; Skanderup, Anders Jacobsen; Ang, Mei‐Kim; Tan, D.S.W.

doi:10.1016/j.jtho.2021.08.144

Cited by 5 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, liquid biopsy techniques development has given the possibility to analyze blood or other fluids for circulating tumor cells, exosomes, RNA and ctDNA. In particular, ctDNA is the most useful and studied biological material as a potential tool to identify MRD in NSCLC (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40). Liquid biopsy has a relevant role in advanced stages of disease, where blood is often intended as complementary or rather a surrogate of tissue biopsy in case it is inadequate for the necessary molecular analysis (41,42).…”

Section: Discussionmentioning

confidence: 99%

“…Tumor tissue was collected intra-operatively in all the studies except for one in which tissue specimen was not provided (30). In addition, 8 out of 13 studies longitudinally collected blood samples during follow-up period, up to four years from surgery, in order to perform the surveillance analysis (30)(31)(32)34,36,37,39,40). The analytical methods used to assess MRD were predominantly based on Next-Generation Sequencing (NGS) (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39), while Polymerase Chain Reaction (PCR)-based methods were applied in one study (40).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…In addition, 8 out of 13 studies longitudinally collected blood samples during follow-up period, up to four years from surgery, in order to perform the surveillance analysis (30)(31)(32)34,36,37,39,40). The analytical methods used to assess MRD were predominantly based on Next-Generation Sequencing (NGS) (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39), while Polymerase Chain Reaction (PCR)-based methods were applied in one study (40). Details of the molecular techniques and the pre-analytical variables are specified in Table 2.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Daysmentioning

confidence: 99%

“…During follow-up surveillance, disease relapse was determined in 11 studies, and it occurred in 14% to 58% of the enrolled patients (29)(30)(31)(32)(33)(34)(35)(36)(37)39,40). ctDNA surveillance analysis was carried out in 8 studies (30)(31)(32)34,36,37,39,40). In details, Qiu et al (39) demonstrated that 27/34 (79.4%) relapsed patients had at least one positive ctDNA during disease surveillance against 14/34 (41.2%) patients who had positive ctDNA status at the landmark timepoint.…”

Section: Daysmentioning

confidence: 99%

See 4 more Smart Citations

Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review

Verzè¹,

Pluchino²,

Leonetti³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Operable stage I-III non-small cell lung cancer (NSCLC) has a high risk of recurrence, mainly due to remnant clones of the disease defined as minimal residual disease (MRD). Adjuvant chemotherapy has a limited efficacy in reducing the risk of relapse, and prognostic as well as predictive biomarkers in this context are currently missing.Methods: We performed a systematic review to evaluate the state of the art about the role of circulating tumor DNA detection through liquid biopsy for the assessment of MRD in resected early-stage NSCLC patients.Results: Among the 650 studies identified, 13 were eligible and included. Although highly heterogeneous, all the studies demonstrated a poor prognosis in patients with post-operative MRD, with a detection rate ranging from 6% to 45%. MRD detection preceded radiographic/clinical recurrence by a mean of 5.5 months. MRD positive patients were most likely to benefit from adjuvant treatment in terms of recurrence-free survival (RFS). Consistently, adjuvant therapy did not minimize the risk of relapse in the MRD negative group.Conclusions: Liquid biopsy has a relevant role in assessing post-surgical MRD in resected NSCLC. Since currently there are no criteria other than stage and risk factors for the choice of adjuvant treatment in this setting, post-operative assessment of MRD through liquid biopsy might be a promising approach to guide the decision.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Daysmentioning

confidence: 99%

Section: Daysmentioning

confidence: 99%

See 3 more Smart Citations

Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review

Verzè¹,

Pluchino²,

Leonetti³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

The expanding role of circulating tumor DNA in resectable non–small cell lung cancer

Morgensztern

2024

Cancer

View full text Add to dashboard Cite

show abstract

Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis

Lu,

Feng,

Guo

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Several recent studies have reported the increasing application of preoperative circulating tumor DNA (ctDNA) as a biomarker of tumor burden for guiding potential postoperative treatment strategies. Methods A meta-analysis of prospective/retrospective cohort studies was conducted to compare the prognosis of preoperatively genetically positive and genetically negative NSCLC patients. The endpoints used in the included studies were overall survival (OS) and recurrence-free survival (RFS). The objective of the meta-analysis was to comprehensively explore the prognostic value of preoperative ctDNA for patients with non-small-cell lung cancer (NSCLC) and its significance in guiding postoperative adjuvant therapy (AT) in patients with NSCLC. Results The preliminary analysis identified 1565 studies, among which only 11 studies fulfilled the eligibility criteria and were finally included in the present systematic review and meta-analysis. The statistical results revealed that the expression of preoperative ctDNA was associated with worse RFS (HR = 3.00; 95% CI 2.26–3.98; I2 = 0%) and OS (HR = 2.77; 95% CI 1.67–4.58; I2 = 0%), particularly in lung adenocarcinoma (LUAD) patients (RFS: HR = 3.46; 95% CI 2.37–5.05; I2 = 0%; OS: HR = 3.52; 95% CI 1.91–6.49; I2 = 0%) and patients with I–II stage of NSCLC (RFS: HR = 2.84; 95% CI 1.88–4.29; I2 = 0%; OS: HR = 2.60; 95% CI 1.43–4.74; I2 = 0%). Moreover, compared to patients with negative preoperative ctDNA, patients with positive preoperative ctDNA presented greater survival benefits (HR = 0.39; 95% CI 0.22–0.67; I2 = 2%) from postoperative AT. Conclusion The evaluation of the prognostic value of preoperative ctDNA revealed that preoperative ctDNA might be used as a prognostic biomarker for patients with LUAD or those with stage I–II NSCLC. In addition, postoperative AT is recommended for NSCLC patients with positive preoperative ctDNA, regardless of the disease stage and subtype.

show abstract

MA07.06 Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer

Cited by 5 publications

References 0 publications

Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review

Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review

The expanding role of circulating tumor DNA in resectable non–small cell lung cancer

Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About